MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/myc.70152

Медицинская библиотека · Mycoses · 2026

Epidemiology and Outcomes of Sporotrichosis: A Descriptive Real-World Analysis From a Global Cohort.

Schapiro Samantha, Pulciano Nicholas, Galindo-Ramirez Julian, Rau Nicholas, Tuells Jose, Agudelo Higuita Nelson Iván, Thompson George R, Chastain Daniel B, Henao-Martínez Andrés F

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Sporotrichosis is a dimorphic fungal infection of increasing global relevance. Although usually cutaneous or lymphocutaneous, disseminated disease occurs in immunocompromised hosts. Large-scale data on its epidemiology, treatment and outcomes remain limited.

OBJECTIVES

To characterise the clinical features, comorbidities, antifungal prescribing patterns and one-year mortality associated with sporotrichosis, with emphasis on patients with HIV and other forms of immunosuppression.

PATIENTS/

METHODS

We performed a retrospective global cohort study using the TriNetX Research Network. Adults (≥ 18 years) diagnosed with sporotrichosis were identified using ICD-9/10 codes (1995-2024). Demographics, comorbidities, laboratory parameters and antifungal prescriptions were analysed. The primary outcome was all-cause mortality at 1 year. Secondary outcomes included hospitalisation and admission to the intensive care unit (ICU).

RESULTS

Among 2124 adults, the mean age was 52 years, and 56.5% were female. Nearly half of the cases originated internationally, with the southeastern United States accounting for the majority of domestic cases. Neoplasms (25%) and diabetes (11%) were the most common comorbidities. Lymphocutaneous disease was uncommon (9%), and disseminated infection occurred in 1% of cases. One-year mortality was 17%, with a higher risk among older adults and those with neoplasms, lymphocutaneous or disseminated infection or hyperferritinemia. Seventeen patients (0.8%) had HIV and were more likely to have pulmonary or disseminated disease. Itraconazole was the most commonly prescribed antifungal (52%), while the use of amphotericin B remained low (< 2%).

CONCLUSIONS

Sporotrichosis causes substantial global mortality. Outcomes appear driven by host factors and gaps in guideline-based management. Earlier recognition, optimised antifungal therapy, and use of inflammatory markers to guide risk stratification may improve outcomes and inform prevention strategies.

Для цитирования: Schapiro Samantha, Pulciano Nicholas, Galindo-Ramirez Julian, Rau Nicholas, Tuells Jose, Agudelo Higuita Nelson Iván, Thompson George R, Chastain Daniel B, Henao-Martínez Andrés F. Epidemiology and Outcomes of Sporotrichosis: A Descriptive Real-World Analysis From a Global Cohort.. Mycoses. 2026. DOI: 10.1111/myc.70152.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.